Drug intelligence / Profile preview

ADAIR

Development stage: Unknown
Modality: Small Molecules
Administration: Intranasal

Overview

ADAIR is an abuse-deterrent, immediate-release formulation of d-amphetamine sulfate, a central nervous system stimulant. It is being developed to mitigate the potential for abuse, particularly through intranasal administration. The drug's mechanism involves increasing the levels of norepinephrine and dopamine in the brain, which are neurotransmitters associated with attention and wakefulness. Clinical trials have evaluated its pharmacokinetics, safety, tolerability, and abuse liability.

Other names: Abuse-Deterrent Immediate-Release FormulationAbuse-Deterrent d-Amphetamine Sulfate Immediate Release Formulation

Targets

TAAR1 (Trace amine-associated receptor 1)NET (Norepinephrine Transporter)VMAT2 (Vesicular monoamine transporter 2)DAT (Dopamine plasma membrane transport protein)

Beyond the preview

Go deeper on ADAIR.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADAIR.

Explore the full profile